Sentien Biotechnologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy
Phase 1
- Conditions
- COVID-19SepsisAcute Kidney Injury
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Sentien Biotechnologies, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04445220
- Locations
- 🇺🇸
University of New Mexico School of Medicine, Albuquerque, New Mexico, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy
Phase 1
- Conditions
- Acute Kidney Injury
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Sentien Biotechnologies, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03015623
- Locations
- 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
News
No news found